SYMPLICITY Results Make Life Difficult For Renal Denervation Programs

The big slice of the device industry, from large-cap firms to venture capitalists, with some stake in the renal denervation opportunity are trying to understand the new reality now that Medtronic’s pivotal Symplicity renal denervation device trial missed its endpoint.

See the original article here:
SYMPLICITY Results Make Life Difficult For Renal Denervation Programs

Tags: , , ,

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Contact Us

Click or drag a file to this area to upload.